Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.

estrogen receptor
biomarker analysis
metastasis
HER2
invasive breast cancer
  • 32 views
  • 18 Oct, 2022
  • 5 locations
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

This phase IIB trial studies how well enzalutamide and paclitaxel before surgery works in treating patients with stage I-III androgen receptor-positive triple-negative breast cancer. Androgens can cause the growth of triple-negative breast cancer. Anti-hormone therapy, such as enzalutamide, prevent androgen from binding to the androgen receptor, thereby decreasing cell growth …

progesterone receptor
biomarker analysis
HER2
absolute neutrophil count
epidermal growth factor receptor
  • 0 views
  • 18 Oct, 2022
  • 2 locations
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

This phase II trial studies how well estradiol works in treating patients with estrogen receptor beta (ER beta) positive, triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Hormone receptors like ER beta allow the body to …

metastasis
HER2
platelet count
monoclonal antibodies
estradiol
  • 0 views
  • 07 Oct, 2022
  • 9 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

subtype is present in approximately 6.6-11.0% of HR+/HER2-negative tumors and might express either HER2, estrogen receptor (ER) or progesterone receptor (PR), we also know that HER2-E is present twice as

progesterone receptor
primary tumor
metastasis
HER2
mammogram
  • 0 views
  • 02 Aug, 2021
  • 15 locations
A Mobile TXT-Based Intervention to Improve Adherence to Adjuvant Hormone Therapy and Symptom Management for BCa Survivors

This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer. Women often require long term therapy with adjuvant hormone therapy to prevent the cancer from returning and to improve overall survival. Side effects from hormone …

cancer
hormone therapy
endocrine therapy
  • 0 views
  • 14 Oct, 2022
  • 5 locations
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

urothelial carcinoma
HER2
lung carcinoma
solid tumour
monoclonal antibodies
  • 139 views
  • 06 Feb, 2022
  • 13 locations
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

lobular carcinoma in situ
metastasis
HER2
absolute neutrophil count
total bilirubin
  • 13 views
  • 15 Jul, 2022
  • 3 locations
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on …

systemic therapy
serum bilirubin level
follicle stimulating hormone
platelet count
  • 63 views
  • 10 Jul, 2022
  • 1 location
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer (LARA)

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

estrogen receptor
metastasis
invasive breast cancer
progesterone receptor
progesterone
  • 0 views
  • 04 Oct, 2022
  • 1 location
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the …

carboplatin/paclitaxel
metastasis
hysterectomy
hormone therapy
tumor cells
  • 5 views
  • 04 Oct, 2022
  • 2 locations